Company Update - MorphoSys

More documents

Recommendations

Info

Partnered Programs Phase 2 Clinical Development Program Partner Disease Target Status CNTO888 CNTO888 CNTO1959 Janssen Biotech Janssen Biotech Janssen Biotech Oncology Idiopathic pulmonary fibrosis CCL2 (MCP-1) CCL2 (MCP-1) Two trials ongoing, one trial completed Novel approach to IPF Psoriasis IL23p19 Phase 2 trial started in December 2011 n.d. Novartis n.d. n.d. Clinical proof of concept achieved n.d. Novartis Ophthalmology n.d. Phase 2 trial started in January 2012 BHQ880 Novartis Osteolytic bone disease DKK-1 Early data show stimulation of bone formation BYM338 Novartis Musculoskeletal n.d. Two phase 2 trials ongoing Gantenerumab Roche Alzheimer‘s disease Amyloid-b Only anti-Aβ antibody being developed in patients with prodromal AD © <strong>MorphoSys</strong> AG Page 26
Partnered Programs Phase 1 Clinical Development Program Partner Disease Phase 1 Start BAY94-9343 Bayer Oncology September 2011 n.d. Boehringer Ingelheim n.d. December 2010 CNTO3157 Janssen Biotech Asthma June 2010 n.d. Janssen Biotech Inflammation / Autoimmune December 2010 n.d. Novartis Inflammation December 2010 OMP-18R5 Oncomed Oncology April 2011 OMP-59R5 Oncomed Oncology December 2010 n.d. Pfizer Oncology December 2010 © <strong>MorphoSys</strong> AG Page 27
Page 1 and 2: Company Update March 2012
Page 3 and 4: Business Strategy Proprietary produ
Page 5 and 6: Strong Track Record of Technologica
Page 7 and 8: 76 Therapeutic Antibody Programs On
Page 9 and 10: MOR103 New Mode of Action in Inflam
Page 11 and 12: MOR103 European Phase 1b/2a Trial i
Page 13 and 14: MOR208 (XmAb5574) - A Novel High-Po
Page 15 and 16: MOR202 - A Novel High-Potential Ant
Page 17 and 18: AbD Serotec Segment Complements The
Page 19 and 20: Balance Sheet and Shareholder Struc
Page 21 and 22: Proprietary Clinical Programs to Ad
Page 23 and 24: Appendix
Page 25: Partnerships: Typical Terms per Pro
Page 29 and 30: Carlumab (CNTO 888): CCL2 Specific
Page 31 and 32: BHQ880: DKK-1 Specific Antibody in
Page 33 and 34: BHQ880: DKK-1 Specific Antibody in
Page 35 and 36: Gantenerumab: Amyloid-ß Specific A
Page 37 and 38: Covering Analysts Institution Conta
Page 39 and 40: © MorphoSys AG Page

Company Update - MorphoSys

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?